Euro Q2 Earnings Preview: GSK, Sanofi, Bayer And Reckitt
Major Europe-based consumer health players GSK, Sanofi, Bayer and Reckitt are all hoping for a sales boost in Q2 following a difficult Q1 due to the almost non-existent cough and cold season. This earnings preview highlights what to look out for as these four firms report their second-quarter results over the coming weeks.
You may also be interested in...
Responding directly to a call from an activist investor to consider selling Consumer Healthcare, GSK says it will evaluate any acquisition proposals it receives. A six-month long process to appoint a CEO to lead the new standalone OTC business is also nearing its conclusion.
Activist investor Elliot Management – which has built up a sizeable stake in GSK – is urging the UK-based pharma giant to remain open to offers for its Consumer Healthcare business and to consider both internal and external candidates for the leadership of the standalone unit.
CDER approves Bayer Healthcare’s azelastine 0.15% nasal antihistamine indicated for seasonal and perennial allergic rhinitis in adults and children 6 and older. Bayer says Astepro Allergy is first steroid-free antihistamine for allergies available OTC in the US and the first indicated for indoor and outdoor allergy relief.